Burstable.Video

CAR-T Lentiviral Particles Transform Cancer Immunotherapy

By Burstable Editorial Team•
Discover CAR-T lentiviral particles from Creative Biogene, offering high-titer production, customization, and quality assurance for effective cancer immunotherapy research and development.

TLDR

  • Creative Biogene's high-titer CAR-T lentiviral particles offer researchers a competitive edge with up to 10^9 IFU/mL, enabling efficient T cell engineering and faster therapy development.
  • CAR-T lentiviral particles work by delivering CAR genes into T cells via ex vivo transduction, ensuring stable integration and expression for targeted cancer cell elimination.
  • This technology advances cancer immunotherapy, offering hope for more effective treatments, including for pediatric solid tumors, potentially improving survival and quality of life.
  • Did you know CAR-T lentiviral particles can be customized to target specific antigens like B7-H3, showing promise against osteosarcoma and nasopharyngeal carcinoma.
Read original article
Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.

WebsiteBlogLinkedInX/Twitter